alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3083 Spinal spheres for use in intervertebral fusion procedures. ( a ) *Identification.* A spinal sphere device is an implanted, solid, spherical, prescription device manufactured from metallic or polymeric materials. The device is inserted into the intervertebral body space of the lumbar spine to provide stabilization and to help promote intervertebral body fusion. The device is to be used with bone graft material.
( b ) *Classification.* Class III.
( c ) *Date premarket approval application (PMA) or notice of completion of product development protocol (PDP) is required.* A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before October 30, 2025, for any spinal sphere for use in intervertebral fusion procedures as identified in paragraph (a) of this section that was in commercial distribution before May 28, 1976, or that has, on or before October 30, 2025, been found to be substantially equivalent to any spinal sphere device for use in intervertebral fusion procedures identified in paragraph (a) of this section, that was in commercial distribution before May 28, 1976. Any other spinal sphere device for use in intervertebral fusion procedures identified in paragraph (a) of this section shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
[88 FR 18990, 18993, Mar. 30, 2023]
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1430 Electroencephalograph test signal generator. ( a ) *Identification.* An electroencephalograph test signal generator is a device used to test or calibrate an electroencephalograph.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 882.9.
[44 FR 51730, Sept. 4, 1979, as amended at 59 FR 63011, Dec. 7, 1994; 66 FR 38807, July 25, 2001]
<TABLE> <S> <C>


<ARTICLE>                     5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                         153,000  
<SECURITIES>                                   253,600  
<RECEIVABLES>                                6,940,000  
<ALLOWANCES>                                   114,000  
<INVENTORY>                                          0  
<CURRENT-ASSETS>                             7,510,000  
<PP&E>                                       1,176,000  
<DEPRECIATION>                                 819,000  
<TOTAL-ASSETS>                               8,141,000  
<CURRENT-LIABILITIES>                        3,777,000  
<BONDS>                                              0  
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0  
<COMMON>                                        32,000    
<OTHER-SE>                                   3,354,000  
<TOTAL-LIABILITY-AND-EQUITY>                 8,141,000  
<SALES>                                     29,091,000  
<TOTAL-REVENUES>                            29,091,000  
<CGS>                                                0  
<TOTAL-COSTS>                               21,711,000  
<OTHER-EXPENSES>                             6,154,000  
<LOSS-PROVISION>                                     0  
<INTEREST-EXPENSE>                             119,000  
<INCOME-PRETAX>                              1,107,000  
<INCOME-TAX>                                   427,000  
<INCOME-CONTINUING>                            680,000  
<DISCONTINUED>                                       0  
<EXTRAORDINARY>                                      0  
<CHANGES>                                            0  
<NET-INCOME>                                   680,000  
<EPS-PRIMARY>                                     0.20  
<EPS-DILUTED>                                     0.20  
                                           


</TABLE>
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.5600 Ptosis crutch. ( a ) *Identification.* A ptosis crutch is a device intended to be mounted on the spectacles of a patient who has ptosis (drooping of the upper eyelid as a result of faulty development or paralysis) to hold the upper eyelid open.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35607, Sept. 14, 1988; 66 FR 38814, July 25, 2001]
<PAGE>   1






                                                                      Exhibit 11


                             SUMMIT TECHNOLOGY, INC.

<TABLE>
                 STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS

<CAPTION>

                                                           THREE MONTHS
                                                          ENDED MARCH 31,
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)             1997                1996
--------------------------------------------------------------------------------


<S>                                                <C>                <C>     
Net loss                                           $ (1,400)           $(3,554)
                                                   ========           ========
                                              
Primary loss per share:                       
                                              
Weighted average common shares                
   outstanding                                       31,020             30,945
                                                   --------           --------
                                              
                                              
Loss per share                                     $   (.05)          $   (.11)
                                                   ========           ========
                                              
Fully diluted loss per share:                 
                                              
Weighted average common shares                
   outstanding                                       31,020             30,945
                                                   --------           --------
                                              
                                              
Loss per share                                     $   (.05)          $   (.11)
                                                   ========           ========
</TABLE>
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.6650 Platelet adhesion test. ( a ) *Identification.* A platelet adhesion test is a device used to determine in vitro platelet function.
( b ) *Classification.* Class II (performance standards).
[45 FR 60608, Sept. 12, 1980]
(a)  A review of Toyota Motor Credit Corporation’s activities and of its performance under the Sale and Servicing Agreement, dated as of August 26, 2015 (the “Sale and Servicing Agreement”), among Toyota Auto Finance Receivables LLC, as seller, Toyota Motor Credit Corporation, as servicer (in such capacity, the “Servicer”) and sponsor, and Toyota Auto Receivables 2015-C Owner Trust, as issuer, during the year ended December 31, 2017 has been made under my supervision.
 
 (b)  To the best of my knowledge, based on such review, the Servicer has fulfilled all of its obligations under the Sale and Servicing Agreement in all material respects throughout the aforementioned period.
 
  
 /s/ Wei Shi
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7955 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7955

              To increase penalties for child pornography.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 11, 2024

  Mrs. Luna (for herself and Mrs. Miller of Illinois) introduced the 
  following bill; which was referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
              To increase penalties for child pornography.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Holding Child Predators Accountable 
Act''.

SEC. 2. POSSESSION OF CHILD PORN.

    (a) Obscenity.--Section 1466A of title 18, United States Code, is 
amended--
            (1) in subsection (a), by striking ``shall be subject to 
        the penalties provided in section 2252A(b)(1), including the 
        penalties provided for cases involving a prior conviction'' and 
        inserting ``shall be fined and punished by death or imprisoned 
        for life''; and
            (2) in subsection (b), by striking ``shall be subject to 
        the penalties provided in section 2252A(b)(2), including the 
        penalties provided for cases involving a prior conviction'' and 
        inserting ``shall be fined and punished by death or imprisoned 
        for life''.
    (b) Exploitation Material.--Subsection (b) of section 2252 of title 
18, United States Code, is amended to read as follows:
    ``(b) Whoever violates, or attempts or conspires to violate 
paragraph (1), (2), (3), or (4) of subsection (a) shall be fined and 
punished by death or imprisoned for life.''.
    (c) Pornography Material.--Subsection (b) of section 2252A of title 
18, United States Code, is amended to read as follows:
    ``(b) Whoever violates, or attempts or conspires to violate 
paragraph (1), (2), (3), (4), (5), (6), or (7) of subsection (a) shall 
be fined and punished by death or imprisoned for life.''.
                                 <all>
```
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 07-4725

UNITED STATES OF AMERICA, Plaintiff - Appellee,

v. WILLIAM HOWARD HARGROVE, Defendant - Appellant. Appeal from the United States District Court for the Eastern District of North Carolina, at Raleigh. James C. Dever III, District Judge. (5:06-cr-00226-D) Submitted: March 26, 2008 Decided: April 11, 2008 Before WILKINSON and NIEMEYER, Circuit Judges, and WILKINS, Senior Circuit Judge. Vacated and remanded by unpublished per curiam opinion. Thomas P. McNamara, Federal Public Defender, G. Alan DuBois, Assistant Federal Public Defender, Raleigh, North Carolina, for Appellant. George E. B. Holding, United States Attorney, Anne M. Hayes, Jennifer P. May-Parker, Assistant United States Attorneys, Raleigh, North Carolina, for Appellee. Unpublished opinions are not binding precedent in this circuit.- 2 - PER CURIAM: William Howard Hargrove pled guilty without a plea agreement to two c ounts of possession with intent to distribute five grams or more of cocaine base, in violation of 21 U.S.C. § 841(a)(1)(2000), and one count of unlawful possession of a firearm by a felon, in violation of 18 U.S.C. § 922(g) (2000). Hargrove appeals his sentence, contending that the district court erred in not considering the inherent inequity of the 100:1 ratio for crack and powder cocaine offenses as the basis for a variance in his case, and that his sentence is consequently unreasonable. We vacate Hargrove’s sentence and remand for resentencing. At sentencing, Hargrove requested a variance based on the sentencing disparity for crack and powder cocaine offenses, but acknowledged our decision in United States v. Kimbrough , 174 F. App’x 798 (4th Cir. 2006) (No. 05-4554) (unpublished) (vacating sentence because the district court deviated from the Guidelines range based on the sentencing disparity for crack and powder cocaine offenses). The district court declined to impose a variance sentence, explicitly relying on United States v. Eura , 440 F.3d 625, 634 (4th Cir. 2006) (holding that the 100:1 ratio may not be used as a basis for a variance sentence). After Hargrove’s brief was filed, however, the Supreme Court reversed this court’s Kimbroughdecision and held that “it would not be an abuse of discretion for a district court to conclude when sentencing a* On remand, the amended Guidelines for crack cocaine offenses, effective November 1, 2007, will apply. - 3 - particular defendant that the crack/powder disparity yields a sentence ‘greater than necessary’ to achieve § 3553(a)’s purposes, even in a mine-run case.” Kimbrough v. United States , 128 S. Ct. 558, 575 (2007). As acknowledged by the Government, the district court did not have the benefit of the Supreme Court’s Kimbrough decision in deciding not to vary below Hargrove’s Guidelines range. Accordingly, we vacate Hargrove’s sentence and remand for resentencing in light of Kimbrough
. * We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

VACATED AND REMANDED
Exhibit 34.2

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Audit and Finance Committee of the Board of Directors

MUFG Americas Holdings Corporation

New York, NY

We have examined management’s assertion, included in the accompanying Management’s Report on Assessment of Compliance with Securities and Exchange Commission (SEC) Regulation AB Servicing Criteria, that MUFG Union Bank, N.A. (the “Bank”), a wholly owned subsidiary of MUFG Americas Holdings Corporation, complied with the servicing criteria set forth in Item 1122(d) of the SEC’s Regulation AB for the asset-backed securities transactions which includes the auto retail installment contracts serviced by American Honda Finance Corporation (the “Platform”) as of and for the year ended March 31, 2018, excluding criteria 1122(d) 1(i), 1(ii), 1(iii), 1(iv), 1(v), 2(i), 2(iii), 2(iv), 2(v), 2(vi), 2(vii), 3(i), 4(i), 4(ii), 4(iii), 4(iv), 4(v), 4(vi), 4(vii), 4(viii), 4(ix), 4(x), 4(xi), 4(xii), 4(xiii), 4(xiv), and 4(xv), which management has determined are not applicable to the activities performed by the Bank with respect to the Platform. Appendix A to management’s assertion identifies the individual asset-backed transactions defined by management as constituting the Platform. Management is responsible for the Bank’s compliance with the servicing criteria other than allocating amounts due to investors with regards to servicing criterion 1122(d)(3)(ii). Our responsibility is to express an opinion on management’s assertion about the Bank’s compliance with the servicing criteria based on our examination.

Our examination was conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States) and, accordingly, included examining, on a test basis, evidence about the Bank’s compliance with the applicable servicing criteria, including tests on a sample basis of the servicing activities related to the Platform, determining whether the Bank performed those selected activities in compliance with the servicing criteria during the specified period, and performing such other procedures as we considered necessary in the circumstances. Our procedures were limited to selected servicing activities performed by the Bank during the period covered by this report and, accordingly, such samples may not have included servicing activities related to each asset-backed transaction included in the Platform. Further, an examination is not designed to detect noncompliance arising from errors that may have occurred prior to the period specified above that may have affected the balances or amounts calculated or reported by the Bank during the period covered by this report. We believe that our examination provides a reasonable basis for our opinion. Our examination does not provide a legal determination on the Bank’s compliance with the servicing criteria.

In our opinion, management’s assertion that the Bank complied with the aforementioned applicable servicing criteria as of and for the year ended March 31, 2018, for the Platform is fairly stated, in all material respects.

/s/ Deloitte & Touche LLP

May 25, 2018
§ 582.7333 Gum ghatti. ( a ) *Product.* Gum ghatti.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 1.1463-1 Tax paid by recipient of income. ( a ) *Tax paid.* If the tax required to be withheld under chapter 3 of the Internal Revenue Code is paid by the beneficial owner of the income or by the withholding agent, it shall not be re-collected from the other, regardless of the original liability therefor. However, this section does not relieve the person that did not withhold tax from liability for interest or any penalties or additions to tax otherwise applicable. See § 1.1441-7(b) for additional applicable rules. See §§ 1.1446-3(e) and (f) and 1.1446(f)-5(a) for application of the rule of this paragraph (a), and for additional rules, in which the withholding tax was required to be paid under section 1446. The references in the previous sentence to § 1.1446-3(e) and (f) apply to partnership taxable years beginning after May 18, 2005, or such earlier time as the regulations under §§ 1.1446-1 through 1.1446-5 apply by reason of an election under § 1.1446-7, and the reference in the previous sentence to § 1.1446(f)-5(a) shall apply to the tax required to be withheld under section 1446(f) for transfers that occur on or after January 29, 2021.
( b ) *Effective date.* Unless otherwise provided in this section, this section applies to failures to withhold occurring after December 31, 2000.
[T.D. 8734, 62 FR 53471, Oct. 14, 1997, as amended by T.D. 8804, 63 FR 72188, Dec. 31, 1998; T.D. 8856, 64 FR 73412, Dec. 30, 1999; T.D. 9200, 70 FR 28741, May 18, 2005; T.D. 9926, 85 FR 76946, Nov. 30, 2020]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7803 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7803

    To amend title 35, United States Code, to provide a good faith 
 exception to the imposition of certain fines, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 22, 2024

   Mr. Issa (for himself and Mr. Johnson of Georgia) introduced the 
  following bill; which was referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
    To amend title 35, United States Code, to provide a good faith 
 exception to the imposition of certain fines, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. GOOD FAITH EXCEPTION TO THE IMPOSITION OF CERTAIN FINES.

    Title 35, United States Code, is amended--
            (1) in section 41(j), by adding before ``be subject'' the 
        following: ``, unless the entity shows that the assertion was 
        made in good faith,''; and
            (2) in section 123(f), by adding before ``be subject'' the 
        following: ``, unless the entity shows that the certification 
        was made in good faith,''.
                                 <all>
```
Docket No. FAA-2016-3989 Dir ID 2014-NM-220-AD
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3660 Shoulder joint metal/polymer semi-constrained cemented prosthesis. ( a ) *Identification.* A shoulder joint metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a shoulder joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a humeral resurfacing component made of alloys, such as cobalt-chromium-molybdenum, and a glenoid resurfacing component made of ultra-high molecular weight polyethylene, and is limited to those prostheses intended for use with bone cement (§ 888.3027).
( b ) *Classification.* Class II. The special controls for this device are: ( 1 ) FDA's: ( i ) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Devices—Part I: Evaluation and Testing,’ ”
( ii ) “510(k) Sterility Review Guidance of 2/12/90 (K90-1),”
( iii ) “Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone or Bone Cement,”
( iv ) “Guidance Document for the Preparation of Premarket Notification (510(k)) Application for Orthopedic Devices,” and
( v ) “Guidance Document for Testing Non-articulating, ‘Mechanically Locked’ Modular Implant Components,”
( 2 ) International Organization for Standardization's (ISO): ( i ) ISO 5832-3:1996 “Implants for Surgery—Metallic Materials—Part 3: Wrought Titanium 6-aluminum 4-vandium Alloy,”
( ii ) ISO 5832-4:1996 “Implants for Surgery—Metallic Materials—Part 4: Cobalt-chromium-molybdenum casting alloy,”
( iii ) ISO 5832-12:1996 “Implants for Surgery—Metallic Materials—Part 12: Wrought Cobalt-chromium-molybdenum alloy,”
( iv ) ISO 5833:1992 “Implants for Surgery—Acrylic Resin Cements,”
( v ) ISO 5834-2:1998 “Implants for Surgery—Ultra-high Molecular Weight Polyethylene—Part 2: Moulded Forms,”
( vi ) ISO 6018:1987 “Orthopaedic Implants—General Requirements for Marking, Packaging, and Labeling,” and
( vii ) ISO 9001:1994 “Quality Systems—Model for Quality Assurance in Design/Development, Production, Installation, and Servicing,” and
( 3 ) American Society for Testing and Materials': ( i ) F 75-92 “Specification for Cast Cobalt-28 Chromium-6 Molybdenum Alloy for Surgical Implant Material,”
( ii ) F 648-98 “Specification for Ultra-High-Molecular-Weight Polyethylene Powder and Fabricated Form for Surgical Implants,”
( iii ) F 799-96 “Specification for Cobalt-28 Chromium-6 Molybdenum Alloy Forgings for Surgical Implants,”
( iv ) F 1044-95 “Test Method for Shear Testing of Porous Metal Coatings,”
( v ) F 1108-97 “Specification for Titanium-6 Aluminum-4 Vanadium Alloy Castings for Surgical Implants,”
( vi ) F 1147-95 “Test Method for Tension Testing of Porous Metal,”
( vii ) F 1378-97 “Standard Specification for Shoulder Prosthesis,” and
( viii ) F 1537-94 “Specification for Wrought Cobalt-28 Chromium-6 Molybdenum Alloy for Surgical Implants.”
[52 FR 33702, Sept. 4, 1987, as amended at 65 FR 17148, Mar. 31, 2000]
State of Washington

40 CFR 52 – Subpart WW

Materials Incorporated by Reference

40 CFR 52.2470(c) and (d)

February 19, 2016

US EPA Region 10

Office of Air, Waste, and Toxics

1200 Sixth Avenue

Seattle, WA 98101